Rb1 loss may serve as a predictive biomarker to guide new targeted therapies for select breast cancers resistant to standard ...
News-Medical.Net on MSN
Study reveals a therapeutic vulnerability in aggressive subtype of triple-negative breast cancer
A new study published today in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer ...
A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center ...
Discover how axolotls and flatworms coordinate regeneration through body-wide signals, revealing a complex healing process.
A published case series reports unexpected cancer remissions linked with fenbendazole use, prompting renewed discussion on ...
Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...
Lunsumio VELO, a CD20xCD3 bispecific antibody, is approved for relapsed or refractory follicular lymphoma after two or more systemic therapies. The GO29781 trial showed a 75% objective response rate ...
Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...
Morning Overview on MSN
Mars trips need stronger cosmic ray shielding, scientists say
Human missions to Mars are edging closer to reality, but the physics of deep space is not cooperating. Outside Earth’s magnetic cocoon, astronauts would be bombarded by high‑energy particles that can ...
Every cell depends on proteins to function and stay healthy. These proteins are made inside the cell from amino acids, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback